OUR EXPERT NETWORK

• Inside The mRNA–LNP Patent Wars: A Q&A With Goodwin On Litigation, Strategy, And What Comes Next

  Patent disputes around mRNA constructs and LNP delivery are intensifying. Goodwin’s Natasha Daughtrey and Bill Christiansen unpack litigation trends, IP strategy, and what RNA developers should expect next.

• MicroRNA Therapeutics In Metabolic Liver Disease: Context-Driven Drug Discovery

  Realizing the therapeutic potential of miRNAs in liver disease requires confronting a problem the field has not fully reckoned with.

• Dual Centrifugation And The Next Phase Of Lipid Nanoparticle Development

  Dual centrifugation enables rapid, small-scale LNP screening with high encapsulation, reproducibility, and preserved RNA integrity — offering a flexible bridge between benchtop discovery and scalable manufacturing.

• The FDA Plausible Mechanism Framework Just Changed Rare Disease Drug Development

  Discover how the new FDA Plausible Mechanism Framework changes the game for rare disease research by formalizing an approval pathway for individualized treatment of ultra-rare genetic diseases.

• The Future Of Kidney Disease Therapeutics: Bringing Nanomedicine To Nephrology

  Nanomedicines are solving the drug delivery problem in kidney disease. The next step: bridging the translational gap to advance these technologies into the clinic.